This study is testing a new drug, BI-1910, alone and with another drug called pembrolizumab, for people with advanced solid tumors. A solid tumor is a mass of cancer cells. The study is in two phases. In Phase 1, researchers will try different doses to find the safest one. In Phase 2a, they will see how well the drugs work and check for any side effects. Participants will get treatments every three weeks. Pembrolizumab is a medicine that helps the immune system fight cancer.

People can join the study if they are at least 18, have an advanced solid tumor, and have already tried standard treatments. They must also agree to regular check-ups and provide tumor samples. Some people cannot join, like those who have active brain cancer or severe heart problems.

• The study involves treatments every 3 weeks.
• Participation requires regular health checks and tumor samples.
• Potential side effects and risks will be monitored closely.